Free Trial
CVE:RX

BioSyent (RX) Stock Price, News & Analysis

BioSyent logo
C$10.81
-0.44 (-3.91%)
(As of 05:17 PM ET)

About BioSyent Stock (CVE:RX)

Key Stats

Today's Range
C$10.81
C$10.81
50-Day Range
C$10.21
C$11.45
52-Week Range
C$7.75
C$11.49
Volume
250 shs
Average Volume
6,085 shs
Market Capitalization
C$125.29 million
P/E Ratio
18.02
Dividend Yield
1.67%
Price Target
N/A
Consensus Rating
N/A

Company Overview

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.

Receive RX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter.

RX Stock News Headlines

Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
BioSyent (CVE:RX) Has Announced A Dividend Of CA$0.045
See More Headlines

RX Stock Analysis - Frequently Asked Questions

BioSyent's stock was trading at C$9.22 at the beginning of 2024. Since then, RX shares have increased by 17.2% and is now trading at C$10.81.
View the best growth stocks for 2024 here
.

BioSyent Inc. (CVE:RX) posted its quarterly earnings data on Monday, August, 26th. The company reported $0.13 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.13. The business earned $8.95 million during the quarter, compared to the consensus estimate of $8.80 million. BioSyent had a net margin of 21.14% and a trailing twelve-month return on equity of 20.88%.

Shares of RX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioSyent investors own include Aurora Cannabis (ACB), Astec Industries (ASTE), Bank of Nova Scotia (BNS), Carnival Co. & (CCL), Cisco Systems (CSCO), Devon Energy (DVN) and Ford Motor (F).

Company Calendar

Last Earnings
8/26/2024
Today
10/31/2024
Next Earnings (Estimated)
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
C$7.15 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$33.82 million
Cash Flow
C$3.52 per share
Book Value
C$3.06 per share

Miscellaneous

Free Float
N/A
Market Cap
C$125.29 million
Optionable
Not Optionable
Beta
0.93
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (CVE:RX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners